Cellectar Biosciences in the News

Myeloma Crowd

Myeloma Crowd

Clinical Trial: Cellectar Biosciences Updates Phase I Results Showing Extended Overall Survival for CLR 131 in Relapsed/Refractory Myeloma
Madison.com

Madison.com

Tech and Biotech: Virent tabs high-level consortium to get its biofuels to market; Cellectar to hold study with UW-Madison
Stockboard.com

Stockboard.com

Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors
Myeloma Crowd

Myeloma Crowd

New Drug Class from Cellectar Biosciences Shows Responses in Early Relapsed/Refractory Myeloma Studies
Financial Buzz

Financial Buzz

Cellectar Biosciences Announces $7.76 Million Registered Direct Offering Priced At-The-Market
Markets Insider

Markets Insider

New Preclinical Data Suggest That Cellectar Biosciences’ PDC Platform Provides Enhanced Outcomes in Combination with External Radiation

Facebook Posts About Cellectar

ICYMI: Cellectar Biosciences had a third quarter earnings call this morning. To hear the webcast play back, click this link: ow.ly/HtA930guNS3 ... See MoreSee Less

View on Facebook

Check out our updated corporate deck including today’s newly announced mOS data, by clicking here: ow.ly/p1cs30gpxrF ... See MoreSee Less

View on Facebook

Cellectar Announces Med. Overall Survival of 26.2 Months from CLR 131 Ph 1 Trial in Advanced Multiple Myeloma ow.ly/5if730gpvZ0 ... See MoreSee Less

View on Facebook

Cellectar Biosciences to Host Conference Call on 11/10/17 to Report Third Quarter 2017 Financial Results and Corporate Performance

ow.ly/SYuX30gjaCm
... See MoreSee Less

View on Facebook

Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma
ow.ly/x75q30g5Phm
... See MoreSee Less

View on Facebook

Sign up here to receive email alerts about Cellectar Biosciences

Investor Relations Email Subscription